3M to Sponsor the 10th annual Asthma & COPD Conference taking place this April in London

SMi are delighted to welcome on board 3M as our latest sponsor at the 10th annual Asthma & COPD conference, taking place on 2nd & 3rd April in London.

LONDON - (EINPresswire via NewMediaWire) - February 26, 2014 - It was announced last week that Invion Limited, will be collaborating with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise. The companies intend to develop 2 drug candidates through to commercialisation, if they prove to be safe and effective when delivered by an inhaler. The potential market size for chronic obstructive pulmonary disease (COPD) or asthma is in excess of $1 billion per year.

Following on from this, Roy Chapple, Technical Business Manager from 3M, will be providing attendees with updates and unique insights into inhalation devices with a focus on recent research, current issues and patient needs at SMi's 10th annual Asthma & COPD Conference this April. Click here for presentation details

The new packed programme also features an extra panel debate led by the Medical Director from Teva, the Managing Director from Therapeutic Challenges Analysis and a Clinical Senior Lecturer from the University of Newcastle. The discussion panel will enable those involved in clinical development to engage with others to compare strategies and ways to enhance processes to improve respiratory development and market access within the pharmaceutical industry.

For further details on newly added presentations, panel debate, exclusive interviews and for a current snap shot of confirmed attendees, download the brochure at www.asthma-copd.co.uk

Event Highlights:

• Four round table discussions to enhance networking capabilities between delegates and sponsors
• Regulatory advice from the MHRA on new inhaled drugs
• Strategies to enhance clinical trial design with key talks from Teva and AstraZeneca
• Case studies from University College London and Theravance Inc. on the late stage developments of combination therapies
• Insight on U-BIOPRED from committee members, Novartis, the British Lung Foundation and the National Heart & Lung Institute

Asthma & COPD
2nd & 3rd APRIL 2014
Marriott Regents Park Hotel
London
www.asthma-copd.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162